EdisonHealthcare

Edison is an investor relations and advisory company, with offices in North America, Europe, the Middle East and AsiaPac.

[Edison @Edison_Inv_Res]

@ErgomedPLC FY21 results showed that adjusted EBITDA of £25.4m was ahead of our estimate of £24.0m and consensus of £23.4m. $ERGO

Read the update here: https://t.co/JVo19cj7ic

[Edison @Edison_Inv_Res]

@DiurnalLtd has announced the extension of its existing marketing and distribution agreement with EffRx Pharmaceuticals, to include Efmody (in addition to Alkindi) in Switzerland. $DNL

Read the flash note here: https://t.co/xxzb17dD8N

[Edison @Edison_Inv_Res]

@Context_Tx R&D webinar covered key takeaways from its five posters presented at the AACR Annual Meeting in April 2022. $CNTX

Update here: https://t.co/uaXlnXhgC9

[Edison @Edison_Inv_Res]

@GSK has announced the acquisition of Sierra Oncology, Sareum’s licensing partner for its CHK1 asset SRA737 (held in partnership with CRT Pioneer Fund) targeting solid tumours. $SAR.L

Update here: https://t.co/gpyfLrYEgN

[Edison @Edison_Inv_Res]

@DiurnalLtd's H122 results were hindered by COVID-19 pandemic restrictions muting the benefits from the H2 CY21 Efmody launches in Germany, UK and Austria. $DNL

Read the update: https://t.co/FdulV77xE1

[Edison @Edison_Inv_Res]

@ReccePharma is a clinical-stage #pharmaceutical company developing a new class of synthetic anti-infectives with novel mechanisms of action suited for treating multi-drug resistant bacteria and emerging viral pathogens. $RCE 🦠

Watch the full video: https://t.co/cbOQEhtJby

[Edison @Edison_Inv_Res]

Welcome to the April edition of the Edison #Healthcare Insight. In this edition we have profiled 36 of our healthcare companies under coverage. 👩🏽‍⚕️

https://t.co/RI46g7TUob

[Edison @Edison_Inv_Res]

On 14 April, Edison client Aditxt $ADTX will host a live investor webinar and business update with its CEO, Amro Albanna. He will provide a corporate overview, information about the Cellvera transaction and answer your questions.

Register here ➡️ https://t.co/timB4fpI8j

[Edison @Edison_Inv_Res]

With all four of @Context_Tx's clinical programs expected to have initial read-outs in 2022, the next few months could be instrumental in shaping the outlook for the company. $CNTX

Read the update here: https://t.co/KgBAkPImU0

[Edison @Edison_Inv_Res]

On 5 April, @SequanaMed announced that it has completed all implantations required for the North American POSEIDON pivotal study assessing the alfapump device for the treatment of recurrent or refractory ascites due to liver cirrhosis. $SEQUA

Update here: https://t.co/gMSVaaYmZ1

[Edison @Edison_Inv_Res]

Last chance to register for our webinar on Wednesday 13 April at 11am ET where you'll get the chance to hear from Edison client Context Therapeutics.

Register here ➡ https://t.co/QVYzv7KXO3

[Edison @Edison_Inv_Res]

@WeAreArovella is progressing on its lead product, ALA-101 targeting blood cancers and has selected a CMO for the production of plasmid and lentiviral vector, with the company intending to finalise iNKT cell manufacturer in Q1 CY22. $ALA

Update here: https://t.co/OHpwszky4w

[Edison @Edison_Inv_Res]

@SigaTech recently reported solid growth in FY21, with revenues up 9.8% y-o-y to $133.7m, as the US Biomedical Advanced Research and Development Authority (BARDA) exercised its procurement option valued at $112.5m. $SIGA

Update here: https://t.co/VCTBpLJKXW

[Edison @Edison_Inv_Res]

In this video, @VolitionRx's president and chief executive officer Cameron Reynolds, group chief financial officer Terig Hughes and veterinary chief executive officer Dr Tom Butera discuss the company’s FY21 results. $VNRX

Watch the full video: https://t.co/dvm02GetP1

[Edison @Edison_Inv_Res]

In this interview, Edison's Pooya Hemami speaks to Doug Hubatsch, recently appointed chief scientific officer of Nicox, a company that develops drugs for eye diseases.

Watch the full interview here: https://t.co/ONqYgwmdEy

[Edison @Edison_Inv_Res]

In this interview, Dr John Husnik, CEO, CSO and co-founder of privately held life sciences company Renaissance BioScience, talks about the global crop protection product market.

Watch the video here: https://t.co/rmnoANYkvu

[Edison @Edison_Inv_Res]

@IRLABThera's inaugural capital markets day outlined the depth of its expanding pipeline and the catalysts that will underpin share momentum over both the near and mid-term. $IRLABA

Read the update here: https://t.co/CUAByXfuSU

[Edison @Edison_Inv_Res]

There are several upcoming catalysts for @KaziaTx. $KZIA

Read the update for more: https://t.co/QCWc1yyzG3

[Edison @Edison_Inv_Res]

Welcome to the March edition of the Edison Healthcare Insight. In this edition we have profiled 39 of our #healthcare companies under coverage.

https://t.co/JVJFb9VnPD

[Edison @Edison_Inv_Res]

In this video, Cantargia's chief executive officer Göran Forsberg provides an update on R&D progress and the upcoming newsflow. $CANTA

Watch the full video here: https://t.co/G3VYmZ16Xu